Perhaps the only thing preventing the seven-foot Andrew Bynum from vaulting to the next level is, ironically, his body.
Bynum will reportedly receive another Synvisc-One injection in his right knee, likely sidelining him for the entire preseason. His agent, David Lee, expects Bynum to be back for the regular season opener against the Denver Nuggets on Oct. 31. The injection, Lee says, should be no cause to worry.
“Just look at it as lubrication for his knees,” Lee said of the Synvisc-One injection that Bynum will receive. The drug is used to treat knee osteoarthritis.
“He’s had them in previous years,” Lee said. “Look at it as WD-40, for lack of a better way of explaining it. He gets them at the start of the season, and he gets them at the all-star break. It’s noninvasive and has nothing to do with the treatment he received in Germany.
Already the beneficiary of a platelet-rich plasma injection in the same knee last month, Bynum’s mounting health issues are becoming a serious concern.
The 24-four-year old center has missed an average of 24 games per year. Last season, Bynum appeared in 60 of a possible 66 games, his healthiest season to date, averaging career highs in points (18.7) and rebounds (11.8).
Should Bynum, acquired in a four-team deal with Orlando, Los Angeles and Denver this offseason, miss significant time this season, Philadelphia would rely on big men Kwame Brown and Spencer Hawes.
Not exactly a pleasant backup plan.